GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.

Dario GiuglianoLorenzo ScappaticcioMiriam LongoPaola CarusoMaria Ida MaiorinoGiuseppe BellastellaAntonio CerielloPaolo ChiodiniKatherine Esposito

Published in: Cardiovascular diabetology (2021)

GLP-1RA have moderate benefits on MACE, and also reduce hospitalization for heart failure and all-cause mortality; they also have robust benefits on reducing the incidence of macroalbuminuria.

Keyphrases

type diabetes
heart failure
glycemic control
rheumatoid arthritis
risk factors
cardiovascular disease
high intensity
left ventricular
insulin resistance
atrial fibrillation
metabolic syndrome